ストックスクリーナーアプリを入手
0.3349
0.53%
-0.00178
アフターアワーズ：
.35
0.0151
+4.51%
前日終値:
$0.3367
開ける：
$0.33
24時間の取引高:
89,109
Relative Volume:
0.54
時価総額：
$3.35M
収益：
$6.98M
当期純損益:
$-12.70M
株価収益率:
-0.0315
EPS:
-10.64
ネットキャッシュフロー:
$-6.94M
1週間 パフォーマンス:
-11.91%
1か月 パフォーマンス:
-5.66%
6か月 パフォーマンス:
-53.05%
1年 パフォーマンス:
-76.25%
1日の値動き範囲:
$0.3223
$0.3535
1週間の範囲:
$0.3169
$0.399
52週間の値動き範囲:
$0.2821
$2.27
Petros Pharmaceuticals Inc Stock (PTPI) Company Profile
名前
Petros Pharmaceuticals Inc
セクター
電話
973-242-0005
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Petros Pharmaceuticals Inc (PTPI) 最新ニュース
Petros Pharmaceuticals Amends President’s Employment Terms - Yahoo Finance
Petros Pharmaceuticals adjusts executive's salary and terms - Investing.com India
Petros Pharmaceuticals adjusts executive's salary and terms By Investing.com - Investing.com South Africa
Petros Pharmaceuticals amends preferred stock terms - Investing.com India
Petros Pharmaceuticals amends preferred stock terms By Investing.com - Investing.com UK
Petros Pharmaceuticals sees two board members resign By Investing.com - Investing.com Australia
Petros Pharmaceuticals sees two board members resign - Investing.com India
Board Reshuffle at Petros Pharmaceuticals Following Resignations - TipRanks
Petros Pharmaceuticals, Inc. Announces Board Resignations - Marketscreener.com
Otsuka and Lundbeck Announce Barbara Corcoran Led Campaign to Raise Awareness of Alzheimer’s Dementia - Pharmaceutical Executive
Petros Pharmaceuticals sets date for 2024 annual meeting - Investing.com
Petros Pharmaceuticals reports high comprehension in drug app study - Investing.com
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - AccessWire
A History of Outperforming Analyst Forecasts and Beating the Odds: Petros Pharmaceuticals Inc (PTPI) - SETE News
Analytical Overview: Petros Pharmaceuticals Inc (PTPI)’s Ratios Tell a Financial Story - The Dwinnex
A stock that deserves closer examination: Petros Pharmaceuticals Inc (PTPI) - US Post News
Petros Pharmaceuticals stock hits 52-week low at $0.28 - Investing.com India
Petros Pharmaceuticals stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 - MSN
Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4% - Defense World
Petros Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com
Joel Baglole - InvestorPlace
Closing Figures: Petros Pharmaceuticals Inc (PTPI)’s Negative Finish at 0.41, Down -3.55 - The Dwinnex
Petros Pharmaceuticals reports promising Web App study - Investing.com
PTPI’s Market Whiplash: -70.74% YTD Decline, -7.41% Plunge in 30 Days - The InvestChronicle
Petros Pharmaceuticals Inc (NASDAQ:PTPI) stock: Is this a flash in the pan today? - US Post News
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - AccessWire
Petros Pharma (NASDAQ:PTPI) Stock Quotes, Forecast and News Summary - Benzinga
Get in on Petros Pharmaceuticals Inc’s (PTPI) buy-in window today! - SETE News
Financial Metrics Exploration: Understanding Petros Pharmaceuticals Inc (PTPI) Through Ratios - The Dwinnex
Petros reports successful study for STENDRA OTC switch By Investing.com - Investing.com Canada
Petros Pharmaceuticals Inc Inc. (PTPI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Petros reports successful study for STENDRA OTC switch - Investing.com
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - AccessWire
Quarterly Metrics: Quick and Current Ratios for Petros Pharmaceuticals Inc (PTPI) – DWinneX - The Dwinnex
Can you still get a good price for Petros Pharmaceuticals Inc (PTPI) Shares at this point? - US Post News
Pioneering change: male contraceptives and the coming OTC revolution - Interesting Engineering
The future of health: male contraceptives and OTC innovation - Interesting Engineering
PTPI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Erectile Dysfunction Drugs Market Size, Share, and Trends 2024 to 2033 - Precedence Research
Petros Pharmaceuticals Inc (PTPI)'s Market Momentum: Closing Strong at 0.41, Down -2.50 – DWinneX - The Dwinnex
Petros Pharmaceuticals Inc (PTPI) did well last session? – US Post News - US Post News
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros ... - AOL
'The Prescription Erectile Dysfunction Market Could Triple if an ED Therapy Becomes Available - The Bharat Express News
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says - Benzinga
Stock Surge: Petros Pharmaceuticals Inc (PTPI) Closes at 0.46, Marking a -13.70 Increase/Decrease – DWinneX - The Dwinnex
Healthy Upside Potential: Petros Pharmaceuticals Inc (PTPI) – Sete News - SETE News
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketBroadcom (NASDAQ ... - Benzinga
Petros Pharmaceuticals Inc (PTPI) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
0.42%
大文字化:
|
ボリューム (24 時間):